Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Isatuximab + VRd or VCd in newly diagnosed transplant-ineligible myeloma

Enrique Ocio • 5 Jun 2020
EHA 2020
Multiple Myeloma Bortezomib Cyclophosphamide Dexamethasone Isatuximab Lenalidomide

Enrique M. Ocio, MD, PhD, of Marqués de Valdecilla University Hospital, Santander, Spain, presents updates from a Phase Ib study of isatuximab, bortezomib, cyclophosphamide and dexamethasone (VCd) or lenalidomide and dexamethasone (VRd) in transplant-ineligible newly diagnosed multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals